和铂医药任命陈友臣为首席财务官-动脉网

Harbour BioMed Appoints Youchen Chen as Chief Financial Officer

CISION 等信源发布 2025-04-10 10:00



可切换为仅中文







CAMBRIDGE, Mass.

马萨诸塞州剑桥市

，

ROTTERDAM, Netherlands

荷兰鹿特丹

and SHANGHAI

上海

，

April 9, 2025

2025年4月9日

/PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics focusing on immunology and oncology, today announced the appointment of Youchen (YC) Chen as Chief Financial Officer. YC will be based in

/PRNewswire/ -- 和铂医药（港交所代码：02142），一家致力于发现和开发专注于免疫学和肿瘤学的新型抗体疗法的全球生物制药公司，今天宣布任命陈友臣（YC Chen）为首席财务官。YC将常驻

Shanghai

上海

and Hong Kong SAR, and report directly to Dr.

和香港特别行政区，并直接向Dr.汇报。

Jingsong Wang

王劲松

, Founder, Chairman, and CEO of Harbour BioMed.

创始人、董事长兼首席执行官。

Since joining Harbour BioMed in 2023, YC has taken on increasing responsibilities across Investor Relations, Corporate Development, Business Development, and Finance. His strategic vision and collaborative leadership have significantly contributed to key strategic transactions, global partnerships and alliances, as well as global financial management and operations.

自2023年加入和铂医药以来，YC在投资者关系、企业发展、业务发展及财务方面承担了越来越多的责任。他的战略眼光与协作领导能力为公司的关键战略交易、全球合作伙伴关系与联盟，以及全球财务管理与运营作出了重要贡献。

In his new role, YC will continue to leverage his expertise to further enhance shareholder value and guide Harbour BioMed through its next phase of strategic development..

在他的新角色中，YC 将继续利用他的专业知识来进一步提升股东价值，并引导 Harbour BioMed 进入其战略发展的下一阶段。

Before joining Harbour BioMed, YC served as Chief Financial Officer at a clinical-stage radiopharmaceutical startup. He was previously Vice President at Credit Suisse China Investment Banking and Capital Market team, advising healthcare and technology companies in

在加入和铂医药之前，YC曾在一家临床阶段的放射性药物初创公司担任首席财务官。他此前曾任职于瑞信中国投资银行和资本市场团队，担任副总裁，为医疗保健和科技公司提供咨询服务。

Greater China

大中华区

on strategic and financing transactions. Prior to Credit Suisse, YC held multiple roles as Head of Corporate Finance at Yidu Tech (2158.HK) and Audit Assistant Manager at KPMG.

在战略和融资交易方面。在加入瑞信之前，YC曾担任医渡科技（2158.HK）企业融资主管和毕马威审计助理经理等多个职位。

Dr.

博士

Jingsong Wang

王劲松

, Founder, Chairman, and CEO of Harbour BioMed, commented: 'YC has brought a strong strategic mindset and deep financial expertise to Harbour BioMed. His ability to lead cross-functional initiatives and drive value creation has made a significant impact across the organization. I'm confident that in his new role as Chief Financial Officer, he will continue to strengthen our financial foundation and support our long-term growth.'.

和铂医药创始人、董事长兼首席执行官评论道：“YC为和铂医药带来了强大的战略思维和深厚的财务专业知识。他领导跨职能项目和推动价值创造的能力对整个组织产生了重大影响。我深信，在他担任首席财务官的新角色中，他将继续夯实我们的财务基础，支持公司的长期发展。”

Youchen Chen

陈友晨

, Chief Financial Officer of Harbour BioMed, added: 'I'm honored to take on the role of Chief Financial Officer at Harbour BioMed. It's been a privilege to work alongside such a dedicated and visionary team. I look forward to continuing our efforts to advance the company's strategic objectives, deliver value to our stakeholders, and support our mission of transforming innovation into impactful therapies.' .

和铂医药首席财务官补充道：“我很荣幸担任和铂医药的首席财务官。能与这样一支专注且富有远见的团队共事是我的荣幸。我期待继续努力推进公司的战略目标，为利益相关者创造价值，并支持我们将创新转化为有影响力的疗法的使命。”

YC holds a bachelor's degree in law from Fudan University and an MBA from the McDonough School of Business at

YC拥有复旦大学法学学士学位和麦克多诺商学院的MBA学位。

Georgetown University

乔治敦大学

. He is also currently pursuing an advanced degree at

。他目前还在攻读

Harvard Medical School

哈佛医学院

。

About Harbour BioMed

关于和铂医药

Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions..

和铂医药（港交所代码：02142）是一家全球生物制药公司，致力于免疫学和肿瘤学领域新型抗体疗法的发现与开发。公司通过内部研发能力、全球战略合作共同发现和开发，以及选择性收购，构建强大且差异化的管线。

Harbour BioMed's proprietary antibody technology platform, Harbour Mice

和铂医药专有的抗体技术平台，Harbour Mice

, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE

，能够以传统的两条重链和两条轻链（H2L2）格式以及仅重链（HCAb）格式生成全人源单克隆抗体。基于HCAb抗体，构建了基于HCAb的免疫细胞接合器（HBICE）。

) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICA

）双特异性抗体技术能够实现传统联合疗法无法达到的肿瘤杀伤效果。此外，基于HCAb的双特异性免疫细胞拮抗剂（HBICA

商标

) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice

）技术赋能了用于免疫和炎症疾病的创新生物药物的开发。通过整合Harbour Mice

, HBICE

，HBICE

, and HBICA

，以及HBICA

商标

with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit

通过单一的B细胞克隆平台，和铂医药打造了高效且独特的抗体发现引擎，用以开发下一代治疗性抗体。欲了解更多信息，请访问

www.harbourbiomed.com

。

SOURCE Harbour BioMed

来源：和铂医药

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &